Research Collaboration

Synairgen plc
12 December 2007



PRESS RELEASE
                                
For Immediate Release                                           12 December 2007
                                                                            


                                  SYNAIRGEN PLC
                         ('Synairgen' or the 'Company')


            Collaboration signed to advance Growth Factor Programme


Synairgen, the company developing novel therapies for asthma and COPD, today
announces that it has entered into a collaboration with Professor David Bassett
of Wayne State University, Michigan, USA, to provide further evidence on the
efficacy of growth factors in a validated preclinical model.


David Bassett is Professor of Occupational and Environmental Health at Wayne
State University School of Medicine and has more than 30 years' experience in
the respiratory area. He has published extensively in the field of pulmonary and
inhalation toxicology. His role in the collaboration will be to evaluate the
effectiveness of Synairgen's growth factor against the asthma-like symptoms that
develop in well-validated preclinical models developed at Wayne State
University. The results of the collaboration are expected by mid 2008.


Richard Marsden, Synairgen's Managing Director, said, 'David Bassett has
extensively researched the effects of allergen on lung inflammation and lung
function. Demonstration that our growth factor can have a positive outcome
against clinically relevant symptoms that develop in his models, together with
our established data generated in human cells from asthmatics, will
significantly increase the confidence in the likelihood of success in the
clinical development programme.'


                                     -Ends-


For further information, please contact:

Synairgen                             Tel: + 44 (0) 2380 512 800
Richard Marsden, Managing Director
John Ward, Finance Director
The Hogarth Partnership               Tel: + 44 (0) 20 7357 9477
Melanie Toyne-Sewell
Simon Hockridge





Notes to Editors


About Synairgen

Synairgen is a drug discovery company founded by Professors Stephen Holgate,
Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new
pharmaceutical products which address the underlying causes of asthma and
chronic obstructive pulmonary disease. Synairgen is listed on AIM (LSE: SNG).


For more information about Synairgen, please see www.synairgen.com.


About Synairgen's Growth Factor Programme

Synairgen's researchers have found that the cells which line the airways (the
epithelium) of asthmatics do not form a robust barrier. This defect in barrier
function may be a key contributor to asthma susceptibility, enabling known
triggers of asthma, such as allergens, pollutants and viruses, to penetrate
through the epithelium to the underlying tissue. Using asthmatic epithelial
cells from its biobank of human tissue, Synairgen has developed a modified
growth factor that can restore barrier function.


About Prof David Bassett

David Bassett has published extensively in the field of pulmonary and inhalation
toxicology and is currently examining the biochemical and patho-physiological
determinants associated with the development of inflammatory diseases of the
lung resulting from exposures to allergens and other airborne substances found
in workplace, home and ambient environments.

For a fuller biography of Prof Bassett, please see

www.cphs.wayne.edu/research/faculty.php








                      This information is provided by RNS
            The company news service from the London Stock Exchange